ADARx Pharmaceuticals, Inc. Common Stock (ADRX) - Total Assets
Based on the latest financial reports, ADARx Pharmaceuticals, Inc. Common Stock (ADRX) holds total assets worth $456.33 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ADARx Pharmaceuticals, Inc. Common Stock operating cash flow efficiency for how efficiently the company converts equity into cash flow.
ADARx Pharmaceuticals, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how ADARx Pharmaceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See ADRX stock price for real-time trading data and today's change.
ADARx Pharmaceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
ADARx Pharmaceuticals, Inc. Common Stock's total assets of $456.33 Million consist of 97.2% current assets and 2.8% non-current assets. Explore ADARx Pharmaceuticals, Inc. Common Stock (ADRX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how ADARx Pharmaceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ADARx Pharmaceuticals, Inc. Common Stock's current assets represent 97.2% of total assets in 2025, an increase from 96.7% in 2024.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2025, up from 6.0% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ADARx Pharmaceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of ADARx Pharmaceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
|
Nanobiotix S.A
PA:NANO
|
France | €45.17 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
ADARx Pharmaceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.98 | 16.18 | 16.18 |
| Quick Ratio | 12.98 | 16.18 | 16.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $407.53 Million | $462.89 Million | $462.89 Million |
ADARx Pharmaceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between ADARx Pharmaceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 3.72 |
| Asset Growth Rate (YoY) | 117.5% |
| Total Assets | $507.65 Million |
| Market Capitalization | $1.89 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values ADARx Pharmaceuticals, Inc. Common Stock's assets at a significant premium (3.72x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ADARx Pharmaceuticals, Inc. Common Stock's assets grew by 117.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ADARx Pharmaceuticals, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of ADARx Pharmaceuticals, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $507.65 Million | +117.45% |
| 2024-12-31 | $233.45 Million | -- |
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple ind… Read more